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Abstract
Background: Very recently, a novel type 2 diabetes risk gene, i.e., MTNR1B, was identified and reported to affect fasting
glycemia. Using our thoroughly phenotyped cohort of subjects at an increased risk for type 2 diabetes, we assessed the
association of common genetic variation within the MTNR1B locus with obesity and prediabetes traits, namely impaired
insulin secretion and insulin resistance.
Methodology/Principal Findings: We genotyped 1,578 non-diabetic subjects, metabolically characterized by oral glucose
tolerance test, for five tagging single nucleotide polymorphisms (SNPs) covering 100% of common genetic variation (minor
allele frequency .0.05) within the MTNR1B locus (rs10830962, rs4753426, rs12804291, rs10830963, rs3781638). In a
subgroup (N=513), insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamp, and in a further subgroup
(N=301), glucose-stimulated insulin secretion was determined by intravenous glucose tolerance test. After appropriate
adjustment for confounding variables and Bonferroni correction for multiple comparisons, none of the tagging SNPs was
reliably associated with measures of adiposity. SNPs rs10830962, rs4753426, and rs10830963 were significantly associated
with higher fasting plasma glucose concentrations (p,0.0001) and reduced OGTT- and IVGTT-induced insulin release
(p#0.0007 and p#0.01, respectively). By contrast, SNP rs3781638 displayed significant association with lower fasting plasma
glucose levels and increased OGTT-induced insulin release (p,0.0001 and p#0.0002, respectively). Moreover, SNP
rs3781638 revealed significant association with elevated fasting- and OGTT-derived insulin sensitivity (p#0.0021). None of
the MTNR1B tagging SNPs altered proinsulin-to-insulin conversion.
Conclusions/Significance: In conclusion, common genetic variation within MTNR1B determines glucose-stimulated insulin
secretion and plasma glucose concentrations. Their impact on b-cell function might represent the prevailing
pathomechanism how MTNR1B variants increase the type 2 diabetes risk.
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Introduction
During the last two years, genome-wide association (GWA)
studies based on tens of thousands of human cases and controls
identified a series of novel type 2 diabetes risk loci including
SLC30A8, HHEX, CDKAL1, IGF2BP2, and CDKN2A/B [1–5]
which were subsequently replicated in other human cohorts and
ethnicities [6–13]. Further investigations in thoroughly pheno-
typed cohorts revealed that these gene variants or, more precisely,
these single nucleotide polymorphisms (SNPs) affect insulin
secretion, but not insulin sensitivity [9;14–20].
Very recently, an additional type 2 diabetes risk gene, i.e.,
MTNR1B, was identified and reported to affect fasting plasma
glucose concentrations [21;22]. MTNR1B (OMIM entry
#600804) is located on human chromosome 11q21–q22 and
encodes one of the two high-affinity G-protein-coupled receptors
for the pineal gland hormone melatonin. Due to its predomi-
nant expression in retina and brain [23], melatonin receptor 1B
is thought to participate in light-dependent functions in the
retina and in melatonin’s neuronal regulation of circadian
rhythmicity and sleep cycles. As certain sleep disorders, such as
obstructive sleep apnea, result from obesity and are associated
with insulin resistance [24;25], MTNR1B could represent a new
interesting candidate gene linking sleep disorders with type 2
diabetes.
Since MTNR1B’s role in the pathogenesis of human obesity and
human prediabetic phenotypes, such as insulin resistance and b-
cell dysfunction, was not yet assessed, it was the aim of the present
study to analyse, using a HapMap approach, the association of
common genetic variation (minor allele frequency, MAF.0.05)
within the MTNR1B locus with state-of-the art measures of
obesity, glucose tolerance, insulin sensitivity, and b-cell function in
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3962a thoroughly phenotyped population at an increased risk for type 2
diabetes.
Methods
Subjects
One thousand six hundred and seventy-five subjects were
recruited from the ongoing Tu ¨bingen Family Study for type 2
diabetes (TU ¨F). The publicly announced call for TU ¨F primarily
addressed non-diabetic individuals from Southern Germany with
family history of type 2 diabetes or diagnosis of impaired fasting
glycemia. At least 99.5% of the TU ¨F participants are of European
ancestry. Selection of the present study cohort was based on the
availability of DNA samples, proinsulin and C-peptide measure-
ments, and complete datasets. From the 1,675 subjects, 97 were
excluded due to newly diagnosed type 2 diabetes. This exclusion
resulted in a non-diabetic cohort of 1,578 subjects (for glucose
tolerance status, see Table 1). 68% of these subjects had a recorded
family history of type 2 diabetes. All participants underwent the
standard procedures of the protocol including medical history and
physical examination, assessment of smoking status and alcohol
consumption habits, routine blood tests, and an oral glucose
tolerance test (OGTT). A subgroup of 513 subjects agreed to
undergo a hyperinsulinemic-euglycemic clamp. Another subgroup
of the clamped subjects (N=301) additionally agreed to undergo
an intravenous glucose tolerance test (IVGTT). The participants
were not taking any medication known to affect glucose tolerance
or insulin secretion. Informed written consent to the study was
obtained from the participants, and the local ethics committee
(Ethik-Kommission der Medizinischen Fakulta ¨t der Universita ¨t
Tu ¨bingen) approved the study protocol.
Selection of tagging SNPs and genotyping
Using the publically available phase II data of the International
HapMap Project derived from a population of Utah residents with
ancestry from Northern and Western Europe (release #23a March
2008, http://www.hapmap.org/index.html.en, [26]), we screened
in silico the complete MTNR1B gene spanning 13.16 kb (two exons,
one intron, located on human chromosome 11q21–q22) as well as
5 kb and 3.5 kb of its 59- and 39-flanking regions, respectively
(Figure 1). Within this locus, 15 informative SNPs with MAF.0.05
were present, and their HapMap linkage disequilibrium data (D’
and r
2 values) are given in Figure 1. Among these, five tagging SNPs
were selected covering 100% of the common genetic variation
(MAF.0.05) within this locus with an r
2.0.8 based on Tagger
analysis using Haploview software (http://www.broad.mit.edu/
mpg/haploview,[27]).ThefivetaggingSNPsrs10830962 C/Gand
rs4753426 T/C (both located in the 59-flanking region of the gene,
Figure 1), rs12804291 C/T, rs10830963 C/G, and rs3781638 A/C
(all three located within the single intron, Figure 1) were selected for
genotyping. For genotyping, DNA was isolated from whole blood
using a commercial DNA isolation kit (NucleoSpin, Macherey &
Nagel, Du ¨ren, Germany). SNPs were genotyped using TaqMan
assays (Applied Biosystems, Foster City, CA, USA). The TaqMan
genotypingreaction wasamplified ona GeneAmpPCR system7000
(50uCf o r2m i n ,9 5 uC for 10 min, followed by 40 cycles of 95uCf o r
15 s and 60uC for 1 min), and fluorescence was detected on an ABI
Prism sequence detector (Applied Biosystems, Foster City, CA,
USA). The TaqMan assays were validated by direct sequencing of
the SNPs in 50 subjects, and both methods gave identical results.
The overall genotyping success rate was 99.9% (rs10830962: 99.9%,
rs4753426: 99.9%, rs12804291: 100%, rs10830963: 100%, and
rs3781638: 99.8%), and rescreening of 3.3% of the subjects with the
TaqMan assay gave 100 % identical results.
Determination of adiposity
Percentage of body fat was measured using bioelectrical
impedance (BIA-101, RJL systems, Detroit, MI, USA). Body mass
index (BMI) was calculated as weight divided by squared height.
Waist circumference was measured in the upright position at the
midpoint between the lateral iliac crest and the lowest rib.
Determination of insulin secretion and insulin sensitivity
After a 10-h overnight fast, all subjects underwent a 75-g
OGTT, and venous blood samples were obtained at 0, 30, 60, 90,
and 120 min for determination of plasma glucose, insulin,
proinsulin, and C-peptide. In those subjects who agreed to
undergo both the IVGTT and the hyperinsulinemic-euglycemic
clamp, the IVGTT was performed prior to the clamp after a 10-h
overnight fast, as described by the Botnia protocol [28]. After
baseline samples (210 and 25 min) had been collected, a glucose
dose of 0.3 g/kg body weight was given at time 0. Blood samples
for the measurement of plasma glucose, insulin, and C-peptide
were obtained at 2, 4, 6, 8, 10, 20, 30, 40, 50, and 60 min. The
hyperinsulinemic-euglycemic clamp was performed starting at
60 min after the IVGTT glucose bolus. To this end, subjects
received a primed infusion of short-acting human insulin (40 mU/
m
2/min) for 120 min. Variable infusion of 20% glucose was
started to clamp the plasma glucose concentration at fasting levels.
Blood samples for the measurement of plasma glucose were
obtained at 5-min intervals. Plasma insulin levels were measured at
baseline (prior to the IVGTT glucose bolus) and at the steady state
(the last 30 min) of the clamp. In subjects who agreed to undergo
the hyperinsulinemic-euglycemic clamp, but not the IVGTT, the
clamp was started after the 10-h overnight fast.
Determination of blood parameters
Plasma glucose was determined using a bedside glucose analyzer
(glucose oxidase method, Yellow Springs Instruments, Yellow
Springs, CO, USA). Plasma insulin and C-peptide concentrations
were measured by commercial chemiluminescence assays for
ADVIA Centaur (Siemens Medical Solutions, Fernwald, Ger-
many) according to the manufacturer’s instructions. Plasma
proinsulin was determined by microparticle enzyme immunoassay
(IBL, Hamburg, Germany). The proinsulin assay has 0% cross-
reactivity with human insulin and C-peptide, the insulin assay has
0% cross-reactivity with proinsulin.
Table 1. Clinical characteristics of the study population.
Gender (female/male) 1044/534
NGT/IFG/IGT/(IFG+IGT) 1139/164/152/123
Age (y) 40613
BMI (kg/m
2) 28.968.2
Waist circumference (cm) 94617
Fasting glucose (mM) 5.1160.55
Glucose, 120 min OGTT (mM) 6.2761.66
Fasting insulin (pM) 63.7652.9
Insulin, 30 min OGTT (pM) 4936393
Data are given as means6SD. BMI–body mass index; IFG–impaired fasting
glucose; IGT–impaired glucose tolerance; NGT–normal glucose tolerance;
OGTT–oral glucose tolerance test.
doi:10.1371/journal.pone.0003962.t001
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The area under the curve (AUC) of plasma glucose levels during
the OGTT was calculated according to the trapezoid method as:
0.5[0.5c(glucose)0+c(glucose)30+c(glucose)60+c(glucose)90+0.5c(glu-
cose)120]. The AUC of plasma insulin, C-peptide, and proinsulin
levels during the OGTT was calculated analogously. Insulin
secretion during the OGTT was assessed by calculating the ratio
AUC C-peptide divided by AUC glucose (AUC C-pep/AUC glc),
first-phase insulin secretion, and the insulinogenic index. First-
phase insulin secretion was estimated from plasma insulin and
glucose concentrations during the OGTT using the formerly
described equation [29]: 1,283+1.829c(insulin)302138.7c(gluco-
se)30+3.772c(insulin)0. The insulinogenic index was calculated as:
[c(insulin)302c(insulin)0]/[c(glucose)302c(glucose)0]. Homeostasis
model assessment of insulin resistance (HOMA-IR) was calculated
as [c(glucose)0?c(insulin)0]/22.5. Insulin sensitivity from OGTT
was estimated as proposed by Matsuda and DeFronzo [30]:
10,000/[c(glucose)0?c(insulin)0?c(glucose)mean?c(insulin)mean]
K.
Clamp-derived insulin sensitivity was calculated as glucose infusion
rate necessary to maintain euglycemia during the last 40 min
(steady state) of the clamp divided by the steady-state insulin
concentration. The disposition index was calculated as first-phase
insulin secretion multiplied by OGTT-derived insulin sensitivity.
Proinsulin conversion was estimated as fasting proinsulin divided
by fasting insulin and, during the OGTT, as AUC proinsulin
divided by AUC insulin. Estimates of hepatic insulin clearance
were obtained during the OGTT by dividing AUC C-peptide by
AUC insulin and mean C-peptide by mean insulin.
Statistical analyses
Hardy-Weinberg equilibrium was tested using x
2 test. Linkage
disequilibrium between the tagging SNPs was analysed using the
JLIN program provided by the Western Australian Institute for
Medical Research (http://www.genepi.org.au/jlin [31]). Prior to
regression analysis, all continuous data were log-transformed in
order to approximate normal distribution. To adjust for
confounding variables, multivariate linear regression models were
applied, and the trait of interest (e.g., BMI, insulin sensitivity
index, or insulin secretion index) was chosen as dependent
variable. Multivariate linear regression analysis was performed
using the least-squares method. Differences in C-peptide levels
during the IVGTT were tested using repeated-measures multi-
variate analysis of variance (MANOVA). Based on testing five
non-linked SNPs and three independent parameters, i.e., measures
of adiposity, measures of insulin secretion, and measures of insulin
action, we performed 15 independent statistical tests in the OGTT
group. Therefore, a p-value ,0.0034 was considered statistically
significant in this group according to Bonferroni correction for
multiple comparisons. In the clamp and IVGTT subgroups, we
tested the five tagging SNPs and only one parameter, i.e., insulin
sensitivity or C-peptide levels, respectively, and therefore per-
formed five independent statistical tests. Accordingly, a p-value
,0.0102 was considered statistically significant in these subgroups.
To perform these analyses, the statistical software package JMP
4.0 (SAS Institute, Cary, NC, USA) was used. Using F-test (one-
way ANOVA with fixed effects), our OGTT study (N=1578) was
sufficiently powered (1-b.0.8, a,0.0034) to detect effect sizes as
small as 10% (additive inheritance model). In the clamp subgroup
(N=513), the study was sufficiently powered to detect effect sizes
as small as 16% (1-b.0.8, a,0.0102; additive inheritance model),
and in the IVGTT subgroup (N=301), we were able to detect
effect sizes as small as 20% (1-b.0.8, a,0.0102; dominant
inheritance model). Power calculations were performed using
G*power 3.0 software available at http://www.psycho.uni-dues-
seldorf.de/aap/projects/gpower/.
Results
Genotyping
We genotyped 1,578 non-diabetic subjects at an increased risk
for type 2 diabetes (clinical characteristics given in Table 1) for the
five MTNR1B tagging SNPs rs10830962, rs4753426, rs12804291,
rs10830963, and rs3781638. As expected for tagging SNPs, these
SNPs were not in strong linkage disequilibrium (Table 2). All SNPs
were in Hardy-Weinberg equilibrium (all p.0.7) and displayed
MAFs very close to those reported by the HapMap project
(http://www.hapmap.org/index.html.en, [26], Table 2).
Anthropometrics, OGTT- and clamp-derived data
These analyses were performed in the additive inheritance
model. After adjustment for gender, age, and family history of
diabetes and Bonferroni correction for multiple comparisons
(corrected a-level: p,0.0034), none of the tagging SNPs was
reliably associated with measuresof adiposity, suchas BMI, body fat
content, and waist circumference (Tables 3 and 4). SNPs
rs10830962, rs4753426, and rs10830963 revealed marked associ-
ations with higher fasting plasma glucose concentrations (all
p,0.0001 after adjustment for gender, age, BMI, and family
history of diabetes), with lower values in all OGTT-derived
measures of insulin release (all p#0.0007 after adjustment for
gender, age, BMI, insulin sensitivity, and family history of diabetes;
Tables 3 and 4), and with lower values of the disposition index (all
p,0.0001after adjustment for gender, age, BMI, and family history
of diabetes). Interestingly, SNP rs3781638 displayed opposite effects
(Table 4): this SNP was associated with reduced fasting plasma
glucose concentrations (p,0.0001), with higher values in all
OGTT-derived measures of insulin release (p#0.0002), and with
a higher value of the disposition index (p,0.0001). Moreover, SNP
rs3781638 showed significant associations with increased OGTT-
derived insulin sensitivity (p,0.0021 after adjustment for gender,
age, BMI, and family history of diabetes) and correspondingly
decreased HOMA-IR (p#0.0015 after analogous adjustment;
Table 4). We then tested whether this SNP also affects hepatic
insulin clearance, a close correlate of liver insulin sensitivity, using
theratiosAUCC-peptide/AUCinsulinandmeanC-peptide/mean
insulin during the OGTT as estimates. After adjustment for gender,
age, BMI, and family history of diabetes, SNP rs3781638 was
significantly associated with these measures in the overall cohort as
well as in the clamped subgroup (all p#0.0199). None of the other
tagging SNPs revealed associations with measures of insulin
sensitivity (Tables 3 and 4). SNP rs12804291 was not associated
with any of the traits tested (Table 3).
After stratification of the cohort in normal glucose-tolerant
subjects (N=1139) and subjects with impaired fasting glycemia
Figure 1. Genomic region of human chromosome 11q21–q22 harbouring the MTNR1B gene and HapMap linkage disequilibrium
data of common (MAF.0.05) informative SNPs within this region. The MTNR1B gene consists of two exons and one intron and spans
13.16 kb from nucleotide 92,342,437 to nucleotide 92,355,596. The analysed region additionally included 5 kb of the 59-flanking region and 3.5 kb of
the 39-flanking region. The locations of the five tagging SNPs (highlighted by red frames) are indicated by arrows. In the upper panel, D’ values are
given in the diamonds (red diamonds without values: D’=1.0). In the lower panel, r
2 values are given in the diamonds (black diamonds: r
2=1.0).
doi:10.1371/journal.pone.0003962.g001
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above to be significantly associated with fasting plasma glucose
concentrations and measures of insulin secretion retained at least
nominal associations with these traits in both subgroups (Supple-
mentary Tables S1, S2, S3 and S4). Interestingly, the association
of SNP rs3781638 with insulin sensitivity remained nominal in
subjects with impaired fasting glycemia and/or impaired glucose
tolerance, but was no longer seen in normal glucose-tolerant
subjects (Supplementary Tables S2 and S4).
We recently reported that type 2 diabetes risk alleles in TCF7L2,
CDKAL1, and SLC30A8 impair proinsulin-to-insulin conversion
[15]. Based on the same parameters, i.e., the ratio fasting
proinsulin divided by fasting insulin and the ratio AUC proinsulin
divided by AUC insulin, we could not detect any reliable
association of the MTNR1B tagging SNPs with proinsulin
conversion (all p$0.04).
IVGTT
In this study, we assessed whether the MTNR1B tagging SNPs
affect glucose-stimulated insulin release. Due to the small sample
size of the IVGTT subgroup, we performed these analyses in the
dominant inheritance model. After adjustment for gender, age,
BMI, insulin sensitivity, and family history of diabetes and
Bonferroni correction for multiple comparisons (corrected a-level:
p,0.0102), two of the four SNPs which were associated with
OGTT-derived insulin secretion, namely rs10830962 and
rs10830963, revealed significantly impaired glucose-stimulated
insulin secretion (p=0.0019and p=0.0077,respectively, Figure2).
The association of SNP rs4753426 with reduced C-peptide levels
showed borderline significance (p=0.0129, Figure 2), and SNP
rs12804291 was not associated at all (p=0.6).
Discussion
With our non-diabetic cohort thoroughly phenotyped for
prediabetic traits, we were recently able to gain important new
information about the pathophysiological role of GWA-derived
type 2 diabetes risk genes [14;15;32;33]. In the present study, we
assessed the impact of common genetic variation within the novel
type 2 diabetes risk gene MTNR1B on the pathogenesis of obesity
and the prediabetic phenotypes insulin resistance and b-cell
dysfunction.
The present study cohort encompassed a wide range of BMI
(16.3–76.9 kg/m
2), body fat content (7–67%), and waist circum-
ference values (52–183 cm). Thus, the lack of association between
common genetic variation within MTNR1B and these measures of
body adiposity, as observed in this study, prompts us to suggest
that this gene plays, if at all, only a minor part in the development
of obesity. Nevertheless, further replication in larger studies is
required to ultimately exclude a role of MTNR1B in this
prediabetic trait.
By contrast, four of the five tagging SNPs revealed clear
associations with insulin release upon an oral glucose load and
three of them showed additional associations with glucose-
stimulated insulin secretion in the IVGTT. Notably, the minor
allele carriers of the latter SNPs, i.e., rs10830962, rs4753426, and
rs10830963, revealed ,20-% reductions in insulin secretion, as
estimated from the IVGTT C-peptide data. Thus, these SNPs’
marked effects on b-cell function are very likely to cause the
alterations in fasting plasma glucose levels seen in this and earlier
studies [21;22]. Furthermore, the association of SNP rs10830962
with 2-h plasma glucose levels might point to this gene’s
association with type 2 diabetes [21;22]. With regard to the
recent identification of melatonin receptors in pancreatic b-cells
[34;35] and melatonin’s regulatory (i.e., inhibitory) effect on
insulin secretion of INS1 insulinoma cells and rat pancreatic islets
in vitro [36–38], it is conceivable that common genetic variation
within MTNR1B affects b-cell function directly.
Interestingly, the minor alleles of the MTNR1B SNPs
rs10830962, rs4753426, and rs10830963 were associated with
reduced insulin secretion, whereas the minor allele of rs3781638
was associated with higher insulin release during the OGTT, and
this opposite effect was accordingly reflected at the level of fasting
plasma glucose concentrations. Since none of the common
informative HapMap SNPs is located within the coding region
of the MTNR1B gene, common genetic variation within this gene
presumably affects MTNR1B expression by altering transcription
factor binding sites. As gene expression is regulated in a very
complex way, frequently involving many transcription factors
simultaneously, it does not appear far-fetched to assume that SNPs
within different cis-acting DNA elements can alter gene expression
in opposite directions.
In addition to its insulin secretion-modulating effect, SNP
rs3781638 also affected insulin sensitivity, as assessed by insulin
and glucose data in the fasting state and during OGTT, and this
effect was most obvious in states known to be associated with
insulin resistance (impaired fasting glycemia and impaired glucose
tolerance). An association with clamp-derived insulin sensitivity
was not observed. This discrepancy could be due to the limited
power of the clamped subgroup. Alternatively, this SNP could
affect hepatic insulin sensitivity which is better reflected by the
former parameters, whereas clamp-derived insulin sensitivity
predominantly represents skeletal muscle insulin sensitivity. Our
finding that SNP rs3781638 was associated with measures of
Table 2. Linkage disequilibrium statistics (D’, r
2) among the five tagging SNPs rs10830962, rs4753426, rs12804291, rs10830963,
and rs3781638 covering the 21.66-kb genomic locus harbouring the MTNR1B gene.
SNP rs10830962 rs4753426 rs12804291 rs10830963 rs3781638
rs10830962 - 0.638 0.326 0.965 0.821
rs4753426 0.288 - 1.000 0.969 0.927
rs12804291 0.018 0.114 - 1.000 0.488
rs10830963 0.581 0.414 0.051 - 1.000
rs3781638 0.357 0.643 0.022 0.330 -
MAF (MAFHapMap) 0.407 (0.383) 0.493 (0.458) 0.106 (0.108) 0.300 (0.300) 0.435 (0.466)
D’ values above empty cells; r
2 values below empty cells. SNP–single nucleotide polymorphism, MAF–minor allele frequency
doi:10.1371/journal.pone.0003962.t002
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PLoS ONE | www.plosone.org 6 December 2008 | Volume 3 | Issue 12 | e3962hepatic insulin clearance not only in the overall cohort but also in
the clamped subgroup argues against a power problem in the
clamped subgroup and favours a role of this SNP in hepatic insulin
sensitivity. To ultimately clarify this issue, further studies with
better, e.g., tracer-based, methods are required.
In conclusion, common genetic variation within MTNR1B
determines glucose-stimulated insulin secretion and plasma
glucose concentrations. The marked impact on b-cell function
might represent the prevailing pathomechanism how genetic
variation within this gene increases the type 2 diabetes risk.
Supporting Information
Table S1 Data represent means6SD. For statistical analysis, data
were log-transformed and adjusted. BMI, body fat, and waist
circumference were adjusted for gender and age. Plasma glucose
levels, indices of insulin sensitivity, and the disposition index were
adjusted for gender, age, and BMI. Other indices of insulin secretion
were adjusted for gender, age, BMI, and ISI (OGTT). p1-p-value
after adjustment as described; p2-p-value afteradditional adjustment
for family history of diabetes. Significance levels withstanding
Bonferroni correction for multiple comparisons are marked in bold
letters. AUC-area under the curve; HOMA-IR-homeostasis model
assessment of insulin resistance; ISI-insulin sensitivity index; SNP-
single nucleotide polymorphism. *subgroup (N=394).
Found at: doi:10.1371/journal.pone.0003962.s001 (0.08 MB
DOC)
Table S2 Data represent means6SD. For statistical analysis,
data were log-transformed and adjusted. BMI, body fat, and waist
circumference were adjusted for gender and age. Plasma glucose
levels, indices of insulin sensitivity, and the disposition index were
adjusted for gender, age, and BMI. Other indices of insulin
secretion were adjusted for gender, age, BMI, and ISI (OGTT).
p1-p-value after adjustment as described; p2-p-value after
additional adjustment for family history of diabetes. Significance
levels withstanding Bonferroni correction for multiple comparisons
are marked in bold letters. AUC-area under the curve; HOMA-
IR-homeostasis model assessment of insulin resistance; ISI-insulin
sensitivity index; SNP-single nucleotide polymorphism. *subgroup
(N=394).
Found at: doi:10.1371/journal.pone.0003962.s002 (0.06 MB
DOC)
Table S3 Data represent means6SD. For statistical analysis,
data were log-transformed and adjusted. BMI, body fat, and waist
circumference were adjusted for gender and age. Plasma glucose
levels, indices of insulin sensitivity, and the disposition index were
adjusted for gender, age, and BMI. Other indices of insulin
secretion were adjusted for gender, age, BMI, and ISI (OGTT).
p1-p-value after adjustment as described; p2-p-value after
additional adjustment for family history of diabetes. Significance
levels withstanding Bonferroni correction for multiple comparisons
are marked in bold letters. AUC-area under the curve; HOMA-
IR-homeostasis model assessment of insulin resistance; ISI-insulin
Table 4. Associations of MTNR1B SNPs rs10830963 and rs3781638 with anthropometrics, insulin sensitivity, and insulin secretion
(N=1578).
SNP rs10830963 rs3781638
Genotype CC CG GG p1 p2 AA AC CC p1 p2
N 778 660 140 - - 501 785 289 - -
Age (y) 40613 39613 4061 3 --3 9 613 40614 39613 - -
BMI (kg/m
2) 29.068.2 28.668.1 29.068.6 0.6 0.3 29.068.6 28.768.1 29.068.0 0.8 0.7
Body fat (%) 31611 31611 30612 0.4 0.3 31611 31611 31610 0.2 0.2
Waist circum-
ference (cm)
94617 93617 94618 0.5 0.5 94618 93617 95617 0.5 0.4
Fasting glucose
(mM)
5.0460.53 5.1460.56 5.2760.59 ,0.0001 ,0.0001 5.1860.58 5.0960.51 5.0260.56 ,0.0001 ,0.0001
Glucose 120 min
OGTT (mM)
6.2061.65 6.3261.64 6.4161.75 0.08 0.07 6.3561.66 6.2661.64 6.1461.69 0.09 0.09
HOMA-IR (U) 2.4862.14 2.4562.18 2.6062.86 0.8 0.8 2.7462.74 2.2861.87 2.5462.07 0.0014 0.0015
ISI, OGTT (U) 16.1610.7 16.3610.6 17.3612.0 0.7 0.5 15.6610.6 16.8610.8 16.1610.9 0.0023 0.0021
ISI, clamp (U)* 0.084
60.058
0.086
60.050
0.088
60.059
0.4 0.4 0.086
60.051
0.083
60.049
0.092
60.073
0.7 0.6
1
st-phase insulin
secretion (nM)
1.3660.87 1.2060.79 1.1660.88 ,0.0001 ,0.0001 1.2760.89 1.2260.77 1.4060.94 ,0.0001 ,0.0001
Insulinogenic
index (?10
29)
1546443 1416158 1056193 ,0.0001 ,0.0001 1366156 1516286 1416584 ,0.0001 ,0.0001
AUC C-pep/AUC
glc (?10
29)
3306109 3136104 2996109 ,0.0001 ,0.0001 3156110 3166103 3406112 0.0001 0.0002
Disposition index
(U)
17.068.8 15.368.3 15.069.7 ,0.0001 ,0.0001 15.168.5 16.468.4 17.469.7 ,0.0001 ,0.0001
Data represent means6SD. For statistical analysis, data were log-transformed and adjusted. BMI, body fat, and waist circumference were adjusted for gender and age.
Plasma glucose levels, indices of insulin sensitivity, and the disposition index were adjusted for gender, age, and BMI. Other indices of insulin secretion were adjusted for
gender, age, BMI, and ISI (OGTT). p1–p-value after adjustment as described; p2–p-value after additional adjustment for family history of diabetes. Significance levels
withstanding Bonferroni correction for multiple comparisons are marked in bold letters. AUC–area under the curve; HOMA-IR–homeostasis model assessment of insulin
resistance; ISI–insulin sensitivity index; SNP–single nucleotide polymorphism.
*subgroup (N=513).
doi:10.1371/journal.pone.0003962.t004
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PLoS ONE | www.plosone.org 8 December 2008 | Volume 3 | Issue 12 | e3962sensitivity index; SNP-single nucleotide polymorphism. *subgroup
(N=119).
Found at: doi:10.1371/journal.pone.0003962.s003 (0.08 MB
DOC)
Table S4 Data represent means6SD. For statistical analysis,
data were log-transformed and adjusted. BMI, body fat, and waist
circumference were adjusted for gender and age. Plasma glucose
levels, indices of insulin sensitivity, and the disposition index were
adjusted for gender, age, and BMI. Other indices of insulin
secretion were adjusted for gender, age, BMI, and ISI (OGTT).
p1-p-value after adjustment as described; p2-p-value after
additional adjustment for family history of diabetes. Significance
levels withstanding Bonferroni correction for multiple comparisons
are marked in bold letters. AUC-area under the curve; HOMA-
IR-homeostasis model assessment of insulin resistance; ISI-insulin
sensitivity index; SNP-single nucleotide polymorphism. *subgroup
(N=119).
Found at: doi:10.1371/journal.pone.0003962.s004 (0.06 MB
DOC)
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